Topics - Content Areas

Science & Research Lasers & Sources Detectors & Imaging Optics Bio & Life Sciences Laser Processing Fiber Optics Software & Accessories Test & Measurement Executive Forum

Resources and Events

Commentary Magazine Videos White Papers Webinars Events Buyer's Guide PhotonicsNXT Engineering Academy Photonics Market Reports Newsletter Archives

User Tools

Subscribe Advertise About Us Contact Us Privacy Policy Terms & Conditions

https://www.facebook.com/pages/Laser-Focus-World/126899915297

https://www.linkedin.com/showcase/laser-focus-world

https://twitter.com/LaserFocusWorld

https://youtube.com/laserfocusworld

Recent Quotes

My Watchlist

Indicators

BioOptics Stock Watch

Markets:

Overview

News

Currencies

International

Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

11.38 +0.14 (+1.25%)

Streaming Delayed Price Updated: 12:41 PM EDT, Aug 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 Next >

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

June 11, 2026

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

May 27, 2026

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference

May 12, 2026

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

May 07, 2026

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

March 05, 2026

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Announces Leadership Changes

December 15, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

November 12, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 06, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

October 23, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in September Investor Conferences

September 02, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 07, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

June 12, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 08, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 06, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 05, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

February 27, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

February 13, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

December 09, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

November 26, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

November 18, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 14, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

November 13, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

August 27, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 15, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

June 27, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

June 24, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

June 20, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

May 30, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

May 16, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

April 30, 2024

From Silence Therapeutics plc

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

https://www.facebook.com/pages/Laser-Focus-World/126899915297

https://www.linkedin.com/showcase/laser-focus-world

https://twitter.com/LaserFocusWorld

https://youtube.com/laserfocusworld

About Us
Contact Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions